Ko YJ - Search Results

1

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Taplin ME, et al. Among authors: ko yj. Cancer Res. 1999 Jun 1;59(11):2511-5. Cancer Res. 1999. PMID: 10363963

2

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. Ko YJ, et al. Clin Cancer Res. 2001 Apr;7(4):800-5. Clin Cancer Res. 2001. PMID: 11309325 Clinical Trial.

3

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL. Stoch SA, et al. Among authors: ko yj. J Clin Endocrinol Metab. 2001 Jun;86(6):2787-91. doi: 10.1210/jcem.86.6.7558. J Clin Endocrinol Metab. 2001. PMID: 11397888

4

Prostate cancer in the older man.

Ko YJ, Bubley GJ. Ko YJ, et al. Oncology (Williston Park). 2001 Sep;15(9):1113-9, 1123-4; discussion 1124-6, 1131. Oncology (Williston Park). 2001. PMID: 11589062 Free article. Review.

5

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE. Taplin ME, et al. Among authors: ko yj. Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9. doi: 10.1016/s0093-7754(01)90152-6. Semin Oncol. 2001. PMID: 11685726 Clinical Trial.

6

Biology of prostate-specific antigen.

Balk SP, Ko YJ, Bubley GJ. Balk SP, et al. Among authors: ko yj. J Clin Oncol. 2003 Jan 15;21(2):383-91. doi: 10.1200/JCO.2003.02.083. J Clin Oncol. 2003. PMID: 12525533 Review.

7

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.

Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Rago RP, et al. Among authors: ko yj. Cancer Chemother Pharmacol. 2003 Apr;51(4):297-305. doi: 10.1007/s00280-003-0573-4. Epub 2003 Mar 13. Cancer Chemother Pharmacol. 2003. PMID: 12721757 Clinical Trial.

8

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.

Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Ko YJ, et al. J Immunother. 2004 May-Jun;27(3):232-9. doi: 10.1097/00002371-200405000-00008. J Immunother. 2004. PMID: 15076141 Clinical Trial.

9

Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.

Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. Ko YJ, et al. J Urol. 2004 Sep;172(3):1140-4. doi: 10.1097/01.ju.0000134698.87862.e6. J Urol. 2004. PMID: 15311058

10

Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers.

Ko YJ, Balk SP. Ko YJ, et al. Curr Pharm Biotechnol. 2004 Oct;5(5):459-70. doi: 10.2174/1389201043376616. Curr Pharm Biotechnol. 2004. PMID: 15544494 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

537 results

Search Page